Overview
Delta sleep-inducing peptide, commonly known as DSIP, is a naturally occurring nonapeptide — meaning it is a short chain of nine amino acids — that was first isolated from the cerebral venous blood of rabbits in the 1970s. It is found in various tissues and fluids in the body, including the brain, and is classified as a neuropeptide due to its presence and activity within the central nervous system. With a molecular weight of approximately 848.8 Da and the molecular formula C35H48N10O15, DSIP has been of interest to researchers studying neurological processes, sleep-wake regulation, and stress responses at the cellular level. Scientists have also investigated its ability to cross the blood-brain barrier, which presents both a practical challenge and a point of interest in preclinical research settings. DSIP is available strictly for laboratory and research purposes and is not intended for human use or consumption.
Research & Bioactivity
Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide that has attracted research interest primarily for its apparent involvement in sleep regulation and central nervous system activity. Researchers have studied DSIP in relation to sleep-wake cycle modulation, with animal model studies — including work using p-chlorophenylalanine (PCPA)-induced insomnia mouse models — examining how the peptide and its fusion variants interact with neurotransmitter systems and potentially influence sleep-related behavior. Studies have also investigated challenges related to DSIP's ability to cross the blood-brain barrier, leading researchers to explore fusion peptide strategies designed to improve its central nervous system accessibility in preclinical settings. Beyond sleep research, DSIP has been examined in broader contexts of neuropeptide signaling, and its structural properties have drawn interest from researchers studying peptide delivery and bioavailability. As with many research peptides, in vitro and animal-based investigations have formed the foundation of the existing literature, and DSIP remains a subject of ongoing scientific inquiry rather than a clinically established agent.
Published Research
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA — 2026
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity. Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages.
Xu H, Wang J, Feng Q, Zhang Y, Ning Z — 2025
Although multi-modality neuroimages have advanced the early diagnosis of Alzheimer's Disease (AD), missing modality issue still poses a unique challenge in the clinical practice. Recent studies have tried to impute the missing data so as to utilize all available subjects for training robust multi-modality models. However, these studies may overlook the modality-specific information inherent in multi-modality data, that is, different modalities possess distinct imaging characteristics and focus on different aspects of the disease. In this paper, we propose a domain-specific information preservation (DSIP) framework, consisting of modality imputation stage and status identification stage, for AD diagnosis with incomplete multi-modality neuroimages. In the first stage, a specificity-induced generative adversarial network (SIGAN) is developed to bridge the modality gap and capture modality-specific details for imputing high-quality neuroimages. In the second stage, a specificity-promoted diagnosis network (SPDN) is designed to promote the inter-modality feature interaction and the classifier robustness for identifying disease status accurately. Extensive experiments demonstrate the proposed method significantly outperforms state-of-the-art methods in both modality imputation and status identification tasks.
secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Mu X, Qu L, Yin L, Wang L, Liu X, et al. — 2024
BACKGROUND: -secreted delta sleep inducing peptide and crossing the blood-brain barrier peptides (DSIP-CBBBP) fusion peptides holds significant promise for its potential sleep-enhancing and neurotransmitter balancing effects. This study investigates these properties using a p-chlorophenylalanine (PCPA) -induced insomnia model in mice, an approach akin to traditional methods evaluating sleep-promoting activities in fusion peptides. AIM OF THE STUDY: The research aims to elucidate the sleep-promoting mechanism of DSIP-CBBBP, exploring its impact on neurotransmitter levels and sleep regulation, and to analyze its composition and structure. MATERIALS AND METHODS: Using a PCPA-induced insomnia mouse model, the study evaluates the sleep-promoting effects of DSIP-CBBBP. The peptide's influence on neurotransmitters such as 5-HT, glutamate, dopamine, and melatonin is assessed. The functions of DSIP-CBBBP are characterized using biochemical and animal insomnia-induced behavior tests and compared without CBBBP. RESULTS: DSIP-CBBBP demonstrates a capacity to modulate neurotransmitter levels, indicated by changes in 5-HT, glutamate, DA, and melatonin. DSIP-CBBBP shows a better restorative effect than DSIP on neurotransmitter imbalance and the potential to enhance sleep. CONCLUSION: The study underscores DSIP-CBBBP potential in correcting neurotransmitter dysregulation and promoting sleep, hinting at its utility in sleep-related therapies.
Sensing the Bactericidal and Bacteriostatic Antimicrobial Mode of Action Using Raman Deuterium Stable Isotope Probing (DSIP) in .
Karlo J, Vijay A, Phaneeswar MS, Singh SP — 2024
The mode of action of antibiotics can be broadly classified as bacteriostatic and bactericidal. The bacteriostatic mode leads to the arrested growth of the cells, while the bacteriocidal mode causes cell death. In this work, we report the applicability of deuterium stable isotope probing (DSIP) in combination with Raman spectroscopy (Raman DSIP) for discriminating the mode of action of antibiotics at the community level. a well-known model microbe, was used as an organism for the study. We optimized the concentration of deuterium oxide required for metabolic activity monitoring without compromising the microbial growth. Our findings suggest that changes in the intensity of the C-D band in the high-wavenumber region could serve as a quantifiable marker for determining the antibiotic mode of action. This can be used for early identification of the antibiotic's mode of action. Our results explore the new perspective that supports the utility of deuterium-based vibrational tags in the field of clinical spectroscopy. Understanding the antibiotic's mode of action on bacterial cells in a short and objective manner can significantly enhance the clinical management abilities of infectious diseases and may also help in personalized antimicrobial therapy.
Electronic Prediction of Chemical Contaminants in Aroma of Brewed Roasted Coffee and Quantification of Acrylamide Levels.
Cascos G, Montero-Fernández I, Marcía-Fuentes JA, Aleman RS, Ruiz-Canales A, et al. — 2024
The aim of this research was to apply an electronic device as indirect predictive technology to evaluate toxic chemical compounds in roasted espresso coffee. Fresh coffee beans were subjected to different thermal treatments and analyzed to determine volatile organic compounds, content of acrylamide and 5-hydroxymethylfurfural, sensory characteristics and electronic nose data. In total, 70 different volatile compounds were detected and grouped into 15 chemical families. The greatest percentage of these compounds were furans, pyrazines, pyridines and aldehydes. The positive aroma detected had the intensity of coffee odor and a roasted aroma, whereas the negative aroma was related to a burnt smell. A linear relationship between the toxic substances and the sensory defect was established. A high sensory defect implied a lower content of acrylamide and a higher content of 5-hydroxymethylfurfural. Finally, electronic signals were also correlated with the sensory defect. This relationship allowed us to predict the presence of these contaminants in the roasted coffee beverage with an indirect method by using this electronic device. Thus, this device may be useful to indirectly evaluate the chemical contaminants in coffee beverages according to their sensory characteristics.